Current vaccine approaches and emerging strategies against herpes simplex virus (HSV). (2nd September 2021)

• Record Type: Journal Article
• Authors: Wijesinghe, Vindya Nilakshi; Farouk, Isra Ahmad; Zabidi, Nur Zawanah; Puniyamurti, Ashwini; Choo, Wee Sim; Lal, Sunil Kumar
• Is Part Of: Expert review of vaccines. Volume 20:Number 9(2021)
• Page Start: 1077
• Page End: 1096
• Publication Date: 2021-09-02
• Subjects: HSV-1 -- HSV-2 -- vaccination -- clinical trials -- vaccine development -- bioinformatics; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1080/14760584.2021.1960162
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: Introduction: Vaccine development for the disease caused by the herpes simplex virus (HSV) has been challenging over the years and is always in dire need of novel approaches for prevention and cure. To date, the HSV disease remains incurable and challenging to prevent. The disease is extremely widespread due to its high infection rate, resulting in millions of infection cases worldwide. Areas covered: This review first explains the diverse forms of HSV-related disease presentations and reports past vaccine history for the disease. Next, this review examines current and novel HSV vaccine approaches being studied and tested for efficacy and safety as well as vaccines in clinical trial phases I to III. Modern approaches to vaccine design using bioinformatics are described. Finally, we discuss measures to enhance new vaccine development pipelines for HSV. Expert opinion: Modernized approaches using in silico analysis and bioinformatics are emerging methods that exhibit potential for producing vaccines with enhanced targets and formulations. Although not yet fully established for HSV disease, we describe current studies using these approaches for HSV vaccine design to shed light on these methods. In addition, we provide up-to-date requirements of immunogenicity, adjuvant selection, and routes of administration.